This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Winners & Losers: Barr

Health stocks were fairly level Thursday amid quarterly results that registered both beyond and below expectations.

Celgene (CELG - Get Report) reported a first-quarter loss of $1.64 billion, or $3.98 a share, largely due to $1.74 billion in charges related to its acquisition of Pharmion, a deal that closed March 8. Sales of multiple myeloma drug Revlimid totaled $286.8 million, supporting Celgene's quarterly revenue of roughly $462 million.

Factoring out one-time charges, the company reported a profit of $159.3 million, or 36 cents a share. The Thomson Reuters consensus target - generally calculated on an adjusted basis -- was 34 cents a share, on a top line of $444 million.

The company also incorporated its acquisition into 2008 estimates, resulting in a 5-cent to 10-cent per-share dilution and guidance of $1.45 a share, on revenue of $2.1 billion. Shares fell 1% to $62.47.

Barr Pharmaceuticals (BRL) fell 23.3% to $38.10 after missing estimates and trimming 2008 guidance.

Its first-quarter profit increased 91% year over year to $23 million, or 21 cents a share, on a GAAP basis. But on an adjusted basis, excluding special items, the company earned 57 cents a share, down from 73 cents a share in the 2007 period. Revenue crept up 2% to $608 million, but also fell short of its portion of the Thomson Reuters view -- which usually factors out special items -- of 78 cents a share on $684.1 million.

Barr also reined in its 2008 estimates, guiding to an earnings range of $2.75 to $3.05 a share, down from its prior view of between $3.05 and $3.35.

Xenoport (XNPT - Get Report) also missed views Wednesday after market close. The company reported a loss of $7.3 million, or 29 cents a share, vs. a loss of $3.3 million, or 14 cents a share, in the year-ago period. Revenue declined 9% to $15 million on lower partner payments. Results missed the Street view of a loss of 2 cents a share on $23.7 million in revenue, and after opening lower, shares fell another 1.9% to $40.22.

Meanwhile, BioCryst (BCRX - Get Report) reported a loss of $13.1 million, or 34 cents a share, widened from a loss of $8.8 million, and 30 cents a share, in the year-ago quarter. Revenue rose to $10.8 million, from $9.2 million. The results fell far below analysts' estimates of a loss of 18 cents a share on revenue of $19.8 million. Shares were down 7% at $2.93.

Both Xenoport and BioCryst are components of the Nasdaq biotechnology index, which edged up 0.4% to 796.42, despite their respective declines.

One stock supporting the index, specialty pharmaceutical company Durect (DRRX - Get Report) shot up 21.6% to $4.62 on Thursday. Its recent quarter benefitted from better expense-revenue alignment. The company met analysts' expectations and narrowed its loss in the recent quarter to $7.8 million, or 11 cents a share, from a loss of $8.8 million, or 13 cents a share, a year prior. Revenue increased 12% to $6.4 million.

In other health stocks, hospice care provider Odyssey Healthcare (ODSY) said its recent quarter benefitted from increasing admissions. The stock added 15.3% to $10 on higher-than-average trading volume.

Net income fell to $1.5 million, or 5 cents a share, from 11 cents a share, a year earlier, but the company said it earned $2.5 million, or 14 cents a share, on an adjusted basis factoring out divested operations and charges.

Adjusted profit and revenue, which rose 21% to $124.8 million, beat the Thomson Reuters target of 10 cents a share on $118.7 million.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs